Introduction
Typical autoimmune responses in patients with systemic lupus erythematosus (SLE) include the production of specific autoantibodies against double-stranded DNA (dsDNA) and the deposition of immune complexes in various organs including the kidneys. The standard therapy regimens are based mainly on immunosuppressive Amir Sharabi, 1 Hava Azulai, 2 Zev M. Sthoeger 2 
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Summary
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by autoantibodies and systemic clinical manifestations. In this study we investigated the beneficial effects on murine lupus accomplished by a peptide based on the sequence of the complementarity-determining region 1 of an anti-DNA autoantibody (hCDR1) when given alone or in combination with cyclophosphamide (CYC), and determined the mechanisms underlying those effects. SLE-afflicted (NZB · NZW) F 1 mice were treated for 12 weeks with injections of hCDR1, CYC or a combination of both drugs. We found that hCDR1 and CYC ameliorated serological and renal manifestations of the diseased mice, down-regulated interferon-c and interleukin-10, and up-regulated transforming growth factor-b. These effects were associated with an increment of naive CD4 + cells at the expense of the number of CD4 + cells with the memory/activated phenotype. Further, the number of CD8 + cells in the diseased mice was increased by the two drugs, resulting in a significant decrease in the CD4 : CD8 ratio. However, whereas the frequency and activity of CD4 + CD25 + CD45RB low regulatory T cells and the expression of cytotoxic T-lymphocyte antigen 4 (CTLA-4) in CD4 + cells were up-regulated by hCDR1 treatment, they were minimally affected following treatment with CYC. CTLA-4 played an important role in the activity of the hCDR1-induced CD4 + CD25 + cells as manifested by down-regulation of CD28 expression, decrease of activation-induced apoptosis, and modulation of the cytokine profile in CD4 + CD25 -cells derived from SLE-afflicted mice. Thus, although the two drugs have similar ameliorative effects, hCDR1 but not CYC elicits regulatory pathways that are of importance for tolerance induction in SLE.
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Our laboratory designed peptides that are based on the complementarity-determining regions (CDR) 1 and 3 of murine or human monoclonal anti-DNA antibodies, bearing a major idiotype designated 16/6Id + . 2, 3 The peptides were shown to be capable of down-regulating autoimmune responses associated with SLE. 2, 4 Furthermore, the peptides were capable of either preventing or treating an established disease that was either induced or developed spontaneously in mice. [4] [5] [6] [7] The hCDR1 (Edratide) is a peptide that is based on the CDR1 of the human anti-DNA monoclonal antibody. Its ameliorative effects on SLE are achieved by tolerance induction through the generation of specific CD4 + CD25 + regulatory T cells (Treg) with transforming growth factor-b (TGF-b)-mediated suppressive capabilities. 8 The resultant effects include down-regulated expression of Fas ligand (FasL, CD178) in CD4 + cells and reduced rate of activation-induced apoptosis in conjunction with downregulation of the pathogenic cytokines, interferon-c (IFN-c) and interleukin-10 (IL-10). 8, 9 In addition, hCDR1 affects specifically T-cell adhesion, chemotaxis and proliferation. 10, 11 In this study we compared the efficiency of hCDR1 and CYC in ameliorating lupus manifestations. The latter drug has been used to treat diffuse proliferative glomerulonephritis in SLE patients. 1 However, because CYC is an alkylating agent with a potent suppressor activity on lymphocytes 12, 13 we also investigated the effects of a combination therapy regimen on the function of hCDR1, and analysed the mechanisms of action of the two drugs.
Materials and methods
Mice
Female (NZB · NZW)F 1 mice were purchased from the Jackson Laboratory (Bar Harbor, ME). The study has been approved by the Animal Care and Use committee of the Weizmann Institute of Science.
Synthetic peptide
A peptide, GYYWSWIRQPPGKGEEWIG (hCDR1) based on the CDR1 of the human anti-DNA monoclonal antibody 3 bearing the 16/6Id was synthesized (solid-phase synthesis by F-moc chemistry) by Polypeptide Laboratories (Torrance, CA) and used in this study. The hCDR1 (Edratide) is currently under clinical development for human SLE by Teva Pharmaceutical Industries Ltd (Netanya, Israel).
Treatment of mice with hCDR1 and CYC
Mice at the age of 6Á5 months were divided into six groups (n ¼ 7 to n ¼ 13) and were injected once a week during a 12-week period using the following protocols: group 1, subcutaneous (s.c.) injections of vehicle, Captisol Ò (sulphobutylether b-cyclodextrin, CyDex Inc., Lenexa, KS), which is used in Edratide formulation to enhance the solubility and stability of the peptide; group 2, s.c. injection of hCDR1 (25 lg/mouse); group 3, intraperitoneal (i.p.) administration of CYC (cyclophosphamide monohydrate; Sigma, St Louis, MO; 1 mg/mouse); group 4, s.c. hCDR1 and i.p. CYC injections; group 5, a 3-week treatment with CYC alone followed by a 9-week treatment with the vehicle alone; group 6, a 3-week treatment with CYC alone followed by a 9-week treatment with hCDR1 alone.
Depletion and enrichment of CD4
+ CD25 + cells
The procedure for depletion and enrichment of CD25 + cells is described elsewhere. 8 Briefly, splenocytes were incubated with anti-CD25-biotinylated monoclonal antibody (clone 7D4; Southern Biotechnology Associates, Birmingham, AL), followed by incubation with antibiotin tetrameric complex (StemCell Technologies, Vancouver, Canada) and magnetic beads (StemCell Technologies). Thereafter the cells were applied into a column that was placed within a magnet stand. The depletion rate of CD25 + cells was > 90%. After removal of the magnet stand CD25 + cells ($80% purity) were eluted from the column.
Enzyme-linked immunosorbent assay (ELISA) for the detection of anti-dsDNA antibodies Maxisorb microtitre plates (Nunk, Roskilde, Denmark) were coated with poly L-lysine (5 lg/ml) (Sigma), followed by coating with k phage dsDNA (5 lg/ml) (Boehringer Mannheim, Mannheim, Germany). After incubation with diluted sera (1 : 10 to 1 : 1250), horseradish peroxidase-labelled goat anti-mouse immunoglobulin G (IgG) (c-chain-specific; Jackson ImmunoResearch, West Grove, PA) was added to the plates, followed by the addition of the substrate, 2,2 0 -azino-bis(3-ethylbenzthiazoline-6-sulphonic acid) (ABTS) (Sigma). 
Antibodies and reagents
Phycoerythrin-conjugated anti-CD4 (anti-CD4-PE; clone GK1.5), allophycocyanin-conjugated anti-CD4 (anti-CD4-APC; clone L3T4), fluorescein isothiocyanate-conjugated anti-CD25 (anti-CD25-FITC; clone 7D4), PE-conjugated anti-cytolytic T-lymphocyte-associated antigen 4 (anti-CTLA-4-PE) (clone 1B8), FITC-conjugated anti-CD8 (clone 53-6.7), and their matched isotype controls were obtained from Southern Biotechnology Associates. Anti-CD45RB-PE (clone 16A), anti-CD62L-PE (clone MEL-14), anti-CD44-FITC (clone IM7), anti-CD28-PE (clone 37.51), anti-CD178-PE (clone MFL3) and their matched isotype controls were purchased from PharMingen (San Diego, CA). Anti-Foxp3-FITC (clone FJK-16 s Set) was purchased from eBioscience (San Diego, CA). Fixation and permeabilization solutions were obtained from Serotec (Oxford, UK). Anti-CTLA-4-neutralizing antibody (clone MR1) was purchased from Southern Biotechnology Associates and its matched isotype control was purchased from Jackson ImmunoResearch.
Flow cytometry analysis
Splenocytes (1 · 10 6 cells) were incubated with the relevant antibody and analysed by fluorescence-activated cell sorter (FACS; Becton Dickinson, Franklin Lakes, NY). For intracellular staining, the cells were incubated with a fixation solution, washed, and then resuspended in permeabilization solution (Serotec).
Terminal deoxynucleotidyltransferase-mediated dUTP nick end labelling (TUNEL) assay
Apoptosis, as demonstrated by fragmented DNA, was determined by using an In Situ Death Detection Kit (Roche, Indianapolis, IN) based on TUNEL technology, according to the protocol supplied by the manufacturer. Cells were analysed by FACS, with forward-scatter and side-scatter gates adjusted to include all cells and to exclude debris and dead cells. Each sample was accompanied by a negative control, comprising UTP labelled with fluorescein, and a positive control, comprising DNase I, grade I (Roche), which was added before the TUNEL staining.
In vitro assays
CD25
-cells derived from vehicle-treated mice were co-incubated (at a ratio of 10 : 1) with enriched CD4 + CD25 + cells obtained from either vehicle-, hCDR1-or CYC-treated mice for 48 hr.
Detection of proteinuria
Proteinuria was measured by a standard semiquantitative test, using an Albustix kit (Bayer Diagnostic, Newbury, UK). Results were graded according to the manufacturer's instructions as: negative, + (0Á3 g/l), + + (1 g/l), + + + (3 g/l) or + + + + (! 20 g/l).
Immunohistology
Frozen cryostat sections (6 lm) were air-dried and fixed in acetone. Thereafter, sections were incubated with FITC-conjugated goat anti-mouse IgG (Jackson ImmunoResearch).
Statistical analysis
The Student's t-test and the Mann-Whitney U-test were used. Values of P 0Á05 were considered significant.
Results
Clinical and serological effects of hCDR1 and CYC on SLE-prone mice SLE-afflicted (NZB · NZW)F 1 female mice at the age of 6Á5 months were treated with weekly injections of hCDR1 and/or CYC during 12 weeks and the clinical and serological effects of the drugs were compared. Table 1 lists the mean values of three independent experiments. The vehicle-treated mice had a significant increase (P ¼ 0Á003) in anti-dsDNA antibodies in their sera at the end of the 12-week treatment period. In contrast, a trend of reduced production of the autoantibodies was observed in the diseased mice that received hCDR1, CYC, or their combination after comparing post-treatment titres with baseline levels. Furthermore, at the end of the experiments the titres of antibodies in the latter treatment groups became significantly lower in comparison to the vehicle-treated group (Table 1) . Notably, SLE-afflicted mice that were treated with CYC for 3 weeks and then given hCDR1 for the next 9 weeks had significant reduced (P ¼ 0Á001) titres of anti-DNA antibodies as compared to mice that were treated for the last 9 weeks with vehicle only (Table 1) .
The evaluation of kidney disease was based on measurements of proteinuria levels and on kidney evaluation for the intensity of immune complex deposits (ICD). Thus, we have found that whereas levels of proteinuria increased substantially in the vehicle-treated ill mice, they decreased in the groups that received hCDR1 and/or CYC as compared to baseline levels (Table 1 ). Yet, mice that were treated with CYC for 3 weeks developed significantly higher levels of proteinuria unless hCDR1 was initiated for the additional 9 weeks, which led to a reduction in the levels of proteinuria. In addition, a significantly low intensity of ICD was observed in the glomeruli of SLEafflicted mice that were treated with all combinations of hCDR1 and CYC compared with the vehicle-treated mice. It appears that the effect of hCDR1 on the glomerular deposits was more prominent than that of CYC (P ¼ 0Á003). Also, the intensity of depositions in the kidneys was lower following administration of the combination of CYC and hCDR1 or of hCDR1 after CYC treatment when compared with injection of CYC alone (P ¼ 0Á04 for both cases).
Effects of hCDR1 and CYC on the cytokine profile of SLE-prone mice Secretion of cytokines was determined in the supernatants of splenocytes after 12 weeks of treatment. Figure 1 demonstrates that supernatants derived from mice that were treated with the vehicle had elevated levels of the pathogenic cytokines IFN-c and IL-10. The latter two cytokines were down-regulated and TGF-b was up-regulated in all treatment groups except for mice injected with a 3-week CYC followed by the vehicle in which IL-10 and TGF-b levels were not affected significantly. However, when hCDR1 followed the initial treatment with CYC, the secretion of the pathogenic cytokines was diminished and that of TGF-b, was up-regulated significantly.
The effects of hCDR1 and CYC on lymphocyte subsets in spleens derived from SLE-prone mice Based on the activated state of the disease, as manifested by the clinical and serological parameters (Table 1) and by the cytokine profile ( Fig. 1) , we wanted to determine the effects of treatment on the activated phenotype of splenocytes. Figure 2 (9) CYC (3) + hCDR1 (9) hCDR1 + CYC 0 500 1000 pg/ml 0 500 1000 pg/ml TGF-β IL-10 Figure 1 . Constitutive secretion of cytokines following treatment with hCDR1 and/or cyclophosphamide (CYC). Pooled splenocytes originating from SLE-afflicted (NZB · NZW)F 1 mice (n ¼ 7 to n ¼ 13 mice/group) at the end of 12 weeks of treatment, were incubated in enriched medium and the supernatants were collected after 48 hr and 72 hr and assessed for levels of IFN-c, IL-10 and TGF-b using ELISA. Mean levels (pg/ml) of duplicates (± SD) in each treatment group are shown. Results are representative of three independent experiments performed. *P 0Á002, P 0Á02, compared with vehicle-treated group. 
Mean results (± SEM) of three independent experiments are presented. 2 Mice at the age of 6Á5 months (n ¼ 13 to n ¼ 23/group) were treated once a week with weekly injections of the vehicle (s.c.), hCDR1 (s.c.) and/or CYC (i.p.) during 12 weeks. 3 Results are of sera from mice that were bled after the end of treatment. Dilution of sera 1 : 250. 4 Proteinuria was always measured at about the same time of day and all mice in an experimental cohort were tested together. Immune complex deposits (ICD) were assessed at death, when the mice reached the age of 9Á5 months. 6 Statistical evaluation was based on the Mann-Whitney U-test to compare post-treatment effects between the vehicle-treated groups and the rest of the treatment groups. determined by flow cytometry. No significant differences could be observed in the relative frequency or in the total number of CD4 + cells in all treated groups (Fig. 2a,b ). Yet, the number of CD4 + cells in mice treated with CYC or CYC followed by the vehicle was the lowest among the groups (Fig. 2b) . It could be seen that treatment of the diseased mice with hCDR1, CYC, or with the combination of both drugs during 12 weeks led to an up-regulation in CD8
+ cells compared to their frequency in the vehicle-treated group (Fig. 2a,b) . Notably, whereas treatment with hCDR1 after the initial 3-week injections with CYC resulted in an up-regulation of CD8 + cells, the frequency of the latter cells was not changed significantly when vehicle was injected after the 3-week CYC regimen. Thus, it appears that injection of both hCDR1 and CYC result in an up-regulation of CD8 + cells leading to a reversal of the CD4 : CD8 ratio. The frequency of T cells with a memory/activated phenotype was also changed as a result of the treatments. As can be seen in Fig. 2(c 
Induction of regulatory T cells
Because CD4 + CD25 + T cells constitute an important compartment through which hCDR1 effectively exerts its ameliorative effects on lupus manifestations 8 we wished to determine the consequence of CYC treatment upon those regulatory cells. Figure 3(a) shows the results of a representative experiment and Fig. 3 . The results presented are after reduction of the background staining obtained with the matched isotype controls, and they represent mean values (± SD) of three independent experiments. *P 0Á05, P 0Á005, compared with vehicle-treated group. the vehicle (Fig. 3; ii.iii). The combined treatment of CYC and hCDR1 also resulted in the up-regulation of the regulatory T cells ( Fig. 3;iv) . Further, a 3-week treatment with CYC followed by a 9-week treatment with hCDR1 led to an increase of the regulatory T cells ( Fig. 3;vi) , as compared to mice that received the vehicle instead of hCDR1 for the last 9 weeks ( Fig. 3;v) .
Expression of CTLA-4 in CD4 + cells is up-regulated by hCDR1 and not by CYC Suppression of activated T cells may occur by the costimulation molecule CTLA-4, which is capable of inhibiting stimulated T cells. We therefore determined the effects of hCDR1 and CYC on the expression of CTLA-4 in CD4 + cells. Figure 4(a) shows the results of a representative experiment and Fig. 4(b) illustrates the mean results of three experiments. Whereas treatment with hCDR1 upregulated the levels of CTLA-4 in CD4 + cells ( Fig. 4 ;ii versus Fig. 4 ;i), treatment with CYC resulted in minimal changes of the latter molecule ( Fig. 4 ;iii versus Fig. 4;i) . Combination of CYC and hCDR1 led to up-regulated expression of CTLA-4, although to a slightly lesser extent than that following treatment with hCDR1 alone (Fig. 4;iv) . The expression of CTLA-4 in CD4 + cells following a 3-week CYC protocol resembled that observed in the vehicle-treated group ( Fig. 4;v) . However, when treatment with hCDR1 was initiated for the last 9 weeks, CTLA-4 expression in the CD4 + cells was up-regulated significantly ( Fig. 4;vi) .
Functional characterization of regulatory T cells
We wanted to know whether the up-regulation in CD4 + CD25 + CD45RB low cells and in CTLA-4 expression following treatment with hCDR1 was manifested in the suppressive capacity of these cells. To this end, CD4 + CD25 + cells derived either from hCDR1-treated or CYC-treated mice were compared. Figure 5 shows the results of two experiments; Fig. 5(a) illustrates that the intracellular expression of Foxp3 in gated CD4 + CD25
+ cells was two-fold higher in the diseased mice following treatment with hCDR1 in comparison with the vehicletreated mice. Treatment with CYC had almost no effect on Foxp3 expression in CD4 + CD25 + cells. In addition, the activation of T lymphocytes decreased in the hCDR1-treated mice, as manifested by down-regulated frequency of CD4 + CD69 + cells compared to their frequency in the vehicle-treated mice, whereas no such effect was observed for CYC-treated mice (Fig. 5b) . To directly address the suppressive capabilities of CD4 + CD25 + cells of hCDR1-treated and CYC-treated mice in vitro assays were performed in which splenocytes (5 · 10 6 ) derived from vehicle-treated SLE-afflicted mice were incubated with enriched CD4 + CD25 + regulatory cells (0Á5 · 10 6 ) originating from either hCDR1 (cells denoted hCDR1-Treg) or CYC-treated mice (cells denoted as CYC-Treg) for 48 hr. As shown in Fig. 5(c) , co-incubation with hCDR1-Treg and not with CYC-Treg resulted in a significantly reduced frequency of CD4 + CD69 + cells. Likewise, the intracellular expression of CTLA-4 in CD4 + cells from vehicle-treated mice was up-regulated only after incubation of the cells with hCDR1-Treg and not with CYC-Treg (Fig. 5d) . Furthermore, hCDR1-Treg and not CYC-Treg could down-regulate the secretion of the pathogenic cytokines, IFN-c and IL-10, in comparison to splenocytes derived from vehicle-treated mice (Fig. 5e ). In conclusion, whereas treatment with hCDR1 resulted in the induction of functional regulatory CD4 + CD25 + cells, the effects of CYC did not involve those regulatory T cells.
Suppression by hCDR1-induced CD4
+ CD25 + cells is mediated by CTLA-4
As CD4 + CD25 + cells are known to play an important mechanistic role in hCDR1-based therapy, 8 we wanted to determine whether the up-regulated expression of CTLA-4 in response to hCDR1 played a role in the suppressive capacity of hCDR1-induced CD4 + CD25 + cells. To this end, CD25
-cells (5 · 10 6 ) derived from splenocytes of the vehicle-treated mice (i.e. Vehicle-CD25 -cells) were incubated with enriched CD4 + CD25 + regulatory cells (0Á5 · 10 6 ) originating from either vehicle (cells denoted ted with hCDR1-Treg in contrast to results following their incubation with Vehicle-Treg. Likewise, hCDR1-Treg and not Vehicle-Treg led to a 50% decrement in the expression of FasL and in the rate of apoptosis of CD4 + cells within the Vehicle-CD25 -cells (Fig. 6c) . The effects of hCDR1-Treg on the expression of CD28, FasL and apoptosis rate of CD4 + cells were diminished following neutralization of CTLA-4 in a dose-dependent manner (Fig. 6b,c) . The addition of the isotype control did not interfere with the activity of hCDR1-Treg. The role of CTLA-4 in the cytokine profile was also tested and the results are illustrated in Fig. 7 . Incubation of Vehicle-CD25
-cells with hCDR1-Treg, but not with Vehicle-Treg, resulted in a significant down-regulation of the pathogenic cytokines IFN-c and IL-10, associated with a significant up-regulation of TGF-b. The effects of hCDR1-Treg on cytokine secretion by Vehicle-CD25 -cells were CTLA-4-dependent because hCDR1-Treg lost their ability to down-regulate the pathogenic cytokines and to up-regulate TGF-b in the presence of a CTLA-4 neutralizing antibody.
Discussion
The main findings of the present study are that hCDR1 and CYC, either separately or in combination, have beneficial effects on the clinical status and cytokine profile of SLE-prone mice. Further, both drugs down-regulate the size of the CD4 + cell population with the activated/memory phenotype leading to the expansion of naive CD4 + cells. The number of CD8 + cells in the diseased mice is increased by the two drugs, resulting in a significant decrease in the CD4 : CD8 ratio. However, in contrast to CYC, treatment with hCDR1 results in a significant upregulation of CD4 + CD25 + CD45RB low regulatory T cells and of CTLA-4 expression, shown here to play an important role in the suppressive capacity of hCDR1-induced CD4 + CD25 + cells. CYC was shown to significantly decrease proteinuria and to reduce the production of anti-DNA autoantibodies in (NZB · NZW)F 1 mice with established lupus. 14, 15 In this study we compared the responses of (NZB · NZW)F 1 mice with established lupus to a 12-week period of treatment with hCDR1, CYC or a combination of these. Thus, we have found that both drugs separately or in combination improved the serological and clinical condition of the SLE-afflicted mice. Notably, the effect of hCDR1 on ICD in the kidneys of the diseased mice was observed to be more prominent than that of CYC. Tsokos et al. described a low threshold of activation for T cells derived from SLE-afflicted mice. 16 Indeed, in the present study 70% of the CD4 + cells had characteristics of activated/memory cells in the diseased mice. Nevertheless, treatment with hCDR1 and/or CYC reduced the number of these cells and significantly increased the pool of naive CD4 + cells. In correlation with the state of activation of the cells, treatment with either drug down-regulated the secretion of IFN-c and IL-10 and up-regulated the immunosuppressive cytokine TGF-b.
The suppression of activity of the splenocytes from (NZB · NZW)F 1 diseased mice by the two drugs was also associated with up-regulation in CD8 + cells. Similarly, reduced numbers of CD8 + cells were observed in other mouse models and also in SLE patients. 17, 18 It is therefore possible that the numerical increase in CD8 + cells may contribute to the suppression of at least part of the autoimmune responses.
In addition to the similar effects of the two drugs our data also indicated significant differences. Thus, hCDR1 /well) with or without two doses of anti-CTLA-4 neutralizing antibody (10 and 20 lg/ml) or its isotype control. Supernatants were collected 48 hr after incubation and assessed for cytokine levels by ELISA. Values (pg/ml) are the mean levels (± SD) of two experiments performed. *P 0Á05, compared with Vehicle-CD25 -cells.
and not CYC was able to induce CD4 + CD25 + regulatory T cells, shown to be protective against autoimmunity 19, 20 and specifically against SLE. 8, 21, 22 We reported that the specific significant amelioration of SLE by hCDR1 is the result of the induction of CD4 + CD25 + cells. 8 The hCDR1-induced CD4 + CD25 + cells possess TGF-b-mediated suppressive capabilities that down-regulate the expression of FasL in CD4 + cells, thereby leading to a reduced rate of activationinduced apoptosis in conjunction with down-regulated secretion of the pathogenic cytokines, IFN-c and IL-10. 8, 9 In contrast, CYC minimally affected and sometimes even down-regulated the frequency and activity of CD4 + CD25 + CD45RB low regulatory cells (Figs 3 and 5) . Nevertheless, the combination of CYC and hCDR1 resulted in a significantly higher frequency of regulatory T cells than following treatment with either the vehicle or CYC alone. Hence, we conclude that the ameliorative effects by CYC were independent of regulatory T cells whereas the latter cells played a key role in the beneficial effects of hCDR1.
The expression of CTLA-4 distinguishes further between CYC and hCDR1. While treatment with CYC had no effect on CTLA-4 expression, treatment with hCDR1 up-regulated CTLA-4 in CD4 + cells significantly (Fig. 4) . Recent studies demonstrated that the addition of CTLA-4Ig to CYC resulted in a higher rate of disease remission in SLE-afflicted (NZB · NZW)F 1 mice. [23] [24] [25] Our results indicate that CTLA-4 is involved in the inhibition of CD4 + cell activation attained by hCDR1-induced CD4 + CD25 + cells. This inhibition was reflected by down-regulation of the CD28 costimulatory molecule, a decrease in the rate of activation-induced apoptosis (Fig. 6) , down-regulation of IFN-c and IL-10, and upregulation of TGF-b (Fig. 7) .
In conclusion, the clinical effects of hCDR1 on lupus manifestations are comparable to those of CYC. Both drugs share common mechanistic elements but there are also major differences. Whereas CYC inhibits lymphocyte activity in a non-specific manner, treatment with hCDR1 is specific and leads to the induction of tolerance by means of specific regulatory T cells and CTLA-4. Based on this, hCDR1 is an effective specific candidate for the treatment of lupus.
